|
|
||||||||
Eur J Cardiothorac Surg 2004;25:931-934
© 2004 Elsevier Science NL
a Department of Paediatric Cardiology, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK
b Department of Clinical Genetics, International Centre for Life, Newcastle upon Tyne NE1 3BZ, UK
Received 14 November 2003; received in revised form 23 January 2004; accepted 28 January 2004.
* Corresponding author. Tel.: +44-191-284-3111; fax: +44-191-223-1314
e-mail: davidxland{at}hotmail.com
| Abstract |
|---|
|
|
|---|
Key Words: Congenital heart disease Life insurance Mortgage
| 1. Introduction |
|---|
|
|
|---|
| 2. Methods |
|---|
|
|
|---|
The CHD population was divided into mild, significant and complex attempting to take into account the original diagnosis, previous surgery and need for future intervention. Mild disease was classified as those needing observation only such as mild aortic or mitral regurgitation, mild pulmonary stenosis and repaired atrial or ventricular septal defect. Significant included those in whom a correction has been attempted but are likely to require further intervention or to have further problems related to their CHD. Such patients included those with tetralogy of Fallot, those who had undergone a Ross procedure, patients with repaired coarctation and repaired complete atrioventricular septal defect. Complex lesions were those where corrective surgery could not be carried out including Eisenmengers, shunt-dependant pulmonary circulations, Fontan circulations and those with the right ventricle supplying the systemic circulation.
To obtain a control group of similar social background and expectations to the CHD population, each adult with CHD was asked to give an identical questionnaire to a friend without CHD. One hundred and seventy-seven controls posted back their questionnaire. We did not specifically control for smoking or illness not related to CHD.
If either case or control had not answered or did not know the answer to a question, the pair was excluded from the analysis for that question.
McNemar's test was used to compare matched pairs and
2 to compare proportions.
Ethics approval was obtained from the joint ethics committee of Newcastle and North Tyneside Health Authority, University of Newcastle upon Tyne and the University of Northumbria and Newcastle.
| 3. Results |
|---|
|
|
|---|
|
|
| 4. Discussion |
|---|
|
|
|---|
It would appear, therefore, that patients with mild defects are inappropriately disadvantaged by their history of CHD. Our study did not investigate the reasons for this but there are a number of possibilities. The patients may not have an adequate understanding of the lesion and give it undue prominence in the application form. It is of interest that a relatively large number was accepted on a subsequent application. One possibility is that a degree of learning had taken place by the patient and the emphasis put on the disease was changed between applications.
Another is that the subsequent application was to a different company. Others have shown that, although in general companies categorise each diagnosis similarly, there are some significant inconsistencies between companies which could be of benefit to the adult with CHD who shops around [7,8]. Some insurance companies may be trying to avoid such patients and any mention of CHD, no matter how trivial, results in a potentially prohibitive loading of the policy. The fact that the cardiologist was not asked by the company to provide a summary or assessment may suggest this.
The finding that patients at the more severe end of the spectrum do not differ significantly from the mild lesions is puzzling. It is possible that the patients may not be aware of the precise diagnosis and state only that they have a congenital heart lesion and are under continuing follow-up but feel completely well [11]. It is surprising from the cardiologist's viewpoint that decisions on life insurance often appear to be made without contacting the supervising cardiologist and that premiums may be based on a diagnosis rather than details of the haemodynamic status of an individual patient. A patient with tetralogy of Fallot and small pulmonary arteries who has required a transannular patch would have the same headline diagnosis as a patient with excellent pulmonary arteries and a virtually preserved pulmonary valve.
The improving survival of patients with CHD to adulthood is creating a new set of problems, many of which although not directly clinical have a major impact on the patients and their families' life. The ability to obtain life insurance is one such problem and the outcome of an individual application depends on the interplay of several factors. The long-term outcome data available to the providers will by definition come from a previous era but as this is the only data available it is likely to have a major impact on the quotation for life insurance. Depending on patients to provide the diagnosis is another potential problem in life insurance and mortgage application as the patients' knowledge of their diagnosis may be poor and is certainly likely to vary widely between patients [11]. Attempts to assign patients neat prognostic groups is difficult as patients with the same condition can be completely different in terms of need for further intervention and long-term outcome [12,13].
The provision of life insurance and mortgage for this miscellaneous population is difficult but the inconsistencies in the current situation need to be addressed by cardiologists, cardiac surgeons, life insurance companies and patient groups.
| Acknowledgments |
|---|
| Footnotes |
|---|
| Appendix A. Conference discussion |
|---|
|
|
|---|
Dr Crossland: The difficulty with that is the insurance companies are trying to make a profit, they are not trying to provide a service to the patients. What we are trying to do now is to discharge some of our patients who are cured or almost cured to help remove their label (of congenital heart disease follow-up). So patients with closed ASD, closed VSD, or balloon dilatation of the pulmonary valve, who are clearly not going to get any worse and can be followed up by the general practitioner, are discharged them from clinic to try and remove their label.
I think that risk assessment for life insurance can be very difficult for these patients.
Dr Ebels: So maybe it's a task for the government to take care of it?
Dr Crossland: Yes. I think that it's reasonable that patients with severe disease don't get life insurance. We have written to insurance companies. For example recently a patient with Fallot's tetralogy could not get life insurance. The company has written back to us and quoted all the (long term) literature on Fallot's, which clearly shows poor outcome because the long-term data for Fallot's is from a different era.
Dr W. Mrowczynski (Poznan, Poland): Were there, in your study group, patients after cardiac transplantation? If so, had this fact an influence on insurance refusal or on increased insurance costs?
Dr Crossland: Many of our patients with severe disease are now being moved toward transplantation. The patients who have been transplanted were excluded from this study.
Dr D. Di Carlo (Rome, Italy): Just to clarify. Were all these patients at the end of the surgical history? That means they had concluded their surgical history, or they required further operation? So that could make a difference for the life insurance, I suppose.
Dr Crossland: Some of these patients, who are being followed up in our adult congenital cardiac clinic, are now being discharged. However, many of the patients (in this study) are from an era when patients were kept indefinitely because of uncertain outcome. So closed VSDs, for example, are now being discharged. I agree with you, however, that a number of patients who have been discharged, who are cured, have been excluded.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 2, 2008; 52(23): e143 - e263. [Full Text] [PDF] |
||||
![]() |
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 2, 2008; 52(23): 1890 - 1947. [Full Text] [PDF] |
||||
![]() |
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, December 2, 2008; 118(23): e714 - e833. [Full Text] [PDF] |
||||
![]() |
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, December 2, 2008; 118(23): 2395 - 2451. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |